An emerging biotech company clearly relies on its scientific prowess to develop an asset that can be efficacious. Throughout development, this scientific “weight” is valuable but too often, promising science is unable to overcome underfunded and under-planned commercial strategy. As emerging biotech companies find the right path to commercialization for their organization, there are key questions to consider when determining if your organization is aligned for commercial success.
Applying a commercial lens from the outset can help companies stay on course and enhance commercial viability.
Register for this webinar to learn more about preparing and aligning your company for commercial success.
Lee Taurman, Executive Vice President, Full-Service Commercial, Syneos Health
Lee Taurman is an experienced life sciences industry Executive and Management Consultant. He specializes in working with clients to develop innovative solutions as they evolve to meet the needs of a changing healthcare and business landscape. This includes developing new integrated services and solutions, reorganizing and restructuring the front and back office to better manage costs and improve services and creating new approaches to strategic planning and execution that unlock shareholder value.
Prior to Syneos Health, Lee led Grant Thornton’s advisory practice for life sciences. His work with clients focused on creating internal and external innovation platforms to deliver business value. He also developed strategies and execution models to harness the power of the “gig economy” and help manage an increasingly externalized non-employee workforce.
Prior to Mylan, Lee spent over a decade as a Management Consultant and Executive at PricewaterhouseCoopers and IBM Global Business Services where he led the Life Sciences Strategy and Transformation practice in the United States.
Lee holds a Master of Business Administration from the Leonard N. Stern School of Business at New York University and a Bachelor of Sciences in Supply Chain Management from the Martin J. Whitman School of Management at Syracuse University.
John Dillman, Chief Commercial Officer, VBI Vaccines
Mr. Dillman joined VBI in 2022 after two years as VBI’s Commercial Lead at Syneos Health, VBI’s partner for the U.S. commercialization of PreHevbrio™ [Hepatitis B Vaccine (Recombinant)], and nearly two decades of commercial sales and marketing leadership experience at Sanofi Pasteur, the human vaccines business of the Sanofi Group. His most recent role was Vice President of Sales, where he was responsible for the direction and oversight of the sales force, marketing and sales training, and telesales organization, with full P&L responsibility delivering over $3 billion of sales annually. While at Sanofi Pasteur, Mr. Dillman was also responsible for all segment, consumer, and digital marketing activities, and spent three years as the General Manager of VaxServe, a Sanofi Pasteur company and a leading specialty distributor of vaccines. Mr. Dillman holds a Bachelor of Business Administration degree from Bridgewater State University, and an M.B.A. with a focus in marketing from West Virginia University.
Brian Johnson, Chief Commercial Officer, Novan
Brian Johnson, MBA, is the Chief Commercial Officer at Novan. In addition to previously serving as the Chief Commercial Officer at Novan from 2015-2018, Mr. Johnson most recently served as a Principal at Two Hearts Group, a pharmaceutical and life science consulting firm where he acted as UCB’s Head, Digital Marketing, Psoriasis in the Global Mission for bimikizumab. Additionally, as the Vice President of Prescription Marketing and Chief Digital Officer at Galderma, Mr. Johnson and his team successfully launched seven products and quadrupled sales from $275 million to over $1 billion led by Epiduo® Clobex® and Oracea.® Other career appointments of note are President, Revian, Inc, Director, Peer to Peer Marketing at Novartis and positions of increasing seniority at Ortho Pharmaceutical Corporation and Medicis. Mr. Johnson holds an MBA from Southern Methodist University and a BS in Business Administration from the University of Kansas.
Who Should Attend?
Chief Medical Officers, and Clinical Development professionals involved in procurement, recruitment and retention, study design, trial site management, and more.
What You Will Learn
Commercial alignment requires asking some critical questions about an organization early in the process:
- Are company goals achievable when transitioning to a commercial organization?
- Is the organization making the right decisions regarding commercial investment?
- Is the organization able to lead their Board and C-suite to a commercial mindset?
Syneos Health (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry leading companies – INC Research and inVentiv Health – we bring together approximately 29,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.
To learn more about how we are shortening the distance from lab to life®, visit syneoshealth.com.